Cannabidivarin alleviates α‐synuclein aggregation via DAF‐16 in Caenorhabditis elegans. Issue 2 (30th December 2022)

• Record Type: Journal Article
• Authors: Wang, Fangru; Jin, Ting; Li, Hongyuan; Long, Houfang; Liu, Ying; Jin, Sha; Lu, Yuyuan; Peng, Yinghua; Liu, Cong; Zhao, Lihui; Wang, Xiaohui
• Is Part Of: FASEB journal. Volume 37:Issue 2(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-30
• Subjects: Caenorhabditis elegans -- cannabidivarin -- DAF‐16 -- Parkinson's disease -- reactive oxygen species; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.202200278RR
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: Cannabidivarin (CBDV), a structural analog of cannabidiol (CBD), has received attention in recent years owing to its anticonvulsant property and potential for treating autism spectrum disorder. However, the function and mechanism of CBDV involved in the progression of Parkinson's disease (PD) remain unclear. In this work, we found that CBDV inhibited α‐synuclein (α‐syn) aggregation in an established transgenetic Caenorhabditis elegans ( C. elegans ). The phenolic hydroxyl groups of CBDV are critical for scavenging reactive oxygen species (ROS), reducing the in vivo aggregation of α‐syn and preventing DAergic neurons from 6‐hydroxydopamine (6‐OHDA)‐induced injury and degeneration. By combining multiple biophysical approaches, including nuclear magnetic resonance spectrometry, transmission electron microscopy and fibrillation kinetics assays, we confirmed that CBDV does not directly interact with α‐syn or inhibit the formation of α‐syn fibrils in vitro. Further cellular signaling investigation showed that the ability of CBDV to prevent oxidative stress, the accumulation of α‐syn and the degeneration of DAergic neurons was mediated by DAF‐16 in the worms. This study demonstrates that CBDV alleviates the aggregation of α‐syn in vivo and reveals that the phenolic hydroxyl groups of CBDV are critical for this activity, providing a potential for the development of CBDV as a drug candidate for PD therapeutics.